JP6794363B2 - 認知の向上のための方法および組成物 - Google Patents

認知の向上のための方法および組成物 Download PDF

Info

Publication number
JP6794363B2
JP6794363B2 JP2017541310A JP2017541310A JP6794363B2 JP 6794363 B2 JP6794363 B2 JP 6794363B2 JP 2017541310 A JP2017541310 A JP 2017541310A JP 2017541310 A JP2017541310 A JP 2017541310A JP 6794363 B2 JP6794363 B2 JP 6794363B2
Authority
JP
Japan
Prior art keywords
klotho
mice
cognitive
polypeptide
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017541310A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509393A (ja
JP2018509393A5 (https=
Inventor
デイナ デュバル
デイナ デュバル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Los Angeles UCLA
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2018509393A publication Critical patent/JP2018509393A/ja
Publication of JP2018509393A5 publication Critical patent/JP2018509393A5/ja
Application granted granted Critical
Publication of JP6794363B2 publication Critical patent/JP6794363B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017541310A 2015-02-06 2016-02-05 認知の向上のための方法および組成物 Active JP6794363B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562113300P 2015-02-06 2015-02-06
US62/113,300 2015-02-06
PCT/US2016/016842 WO2016127097A1 (en) 2015-02-06 2016-02-05 Methods and compositions for improved cognition

Publications (3)

Publication Number Publication Date
JP2018509393A JP2018509393A (ja) 2018-04-05
JP2018509393A5 JP2018509393A5 (https=) 2019-03-22
JP6794363B2 true JP6794363B2 (ja) 2020-12-02

Family

ID=56564770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017541310A Active JP6794363B2 (ja) 2015-02-06 2016-02-05 認知の向上のための方法および組成物

Country Status (8)

Country Link
US (6) US10632180B2 (https=)
EP (2) EP3957317A1 (https=)
JP (1) JP6794363B2 (https=)
CN (2) CN107405382A (https=)
AU (2) AU2016215080B2 (https=)
CA (1) CA2974988A1 (https=)
HK (1) HK1246193A1 (https=)
WO (1) WO2016127097A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107405382A (zh) 2015-02-06 2017-11-28 加利福尼亚大学董事会 用于改善认知的方法和组合物
WO2017085317A1 (en) * 2015-11-19 2017-05-26 Universitat Autonoma De Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments
JP2018184369A (ja) * 2017-04-26 2018-11-22 株式会社明治 知的作業能力向上用組成物および認知能力向上用組成物
WO2019140250A1 (en) * 2018-01-12 2019-07-18 New York University SOLUBLE α-KLOTH PROTEINS, PROTEIN FRAGMENTS, AND USES THEREOF
US20210106579A1 (en) * 2018-05-17 2021-04-15 Neuralstem, Inc. Amelioration of cognitive and motor deficits associated with alzheimer's
WO2020106997A1 (en) * 2018-11-21 2020-05-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods and materials for reducing age-related striated muscle and cognitive decline
EP4103223A4 (en) 2020-02-12 2024-05-29 The Regents of the University of California PLATELET FACTORS AND COGNITIVE IMPROVEMENT
US20230123357A1 (en) * 2020-03-04 2023-04-20 The Regents Of The University Of California Use of downstream factors in the klotho pathway to assess klotho activity
WO2024084400A2 (en) * 2022-10-17 2024-04-25 Bio Immunitas Ltd. Alpha 2 macroglobulin, soluble klotho and methods of use thereof
WO2024092238A1 (en) * 2022-10-28 2024-05-02 Unity Biotechnology, Inc. Klotho polypeptide or polynucleotide for improving cognition
EP4434534A1 (en) 2023-03-22 2024-09-25 ADvantage Therapeutics, Inc. Klotho mrna
CN117797249A (zh) * 2023-11-14 2024-04-02 苏州祥沁医疗科技有限公司 基于mRNA的抗衰老抗老年痴呆预防及治疗疫苗
WO2025168038A1 (en) * 2024-02-07 2025-08-14 Kunming Institute Of Zoology, Chinese Academy Of Sciences Methods and compositions for ameliorating impairment of regenerative and cognitive function

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452720A (en) 1980-06-04 1984-06-05 Teijin Limited Fluorescent composition having the ability to change wavelengths of light, shaped article of said composition as a light wavelength converting element and device for converting optical energy to electrical energy using said element
US4732863A (en) 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
US5330900A (en) 1987-12-31 1994-07-19 Tropix, Inc. Chemiluminescent 3-(substituted adamant-2'-ylidene) 1,2-dioxetanes
US5227487A (en) 1990-04-16 1993-07-13 Molecular Probes, Inc. Certain tricyclic and pentacyclic-hetero nitrogen rhodol dyes
ES2281112T3 (es) 1996-12-26 2007-09-16 Kyowa Hakko Kogyo Co., Ltd. Proteina que presenta una actividad de supresion del envejecimiento.
US7244826B1 (en) 1998-04-24 2007-07-17 The Regents Of The University Of California Internalizing ERB2 antibodies
US20050037954A1 (en) * 2001-03-23 2005-02-17 Masaki Hirashima Novel agents for ameliorating motor disorder
US20040101874A1 (en) 2002-04-12 2004-05-27 Mitokor Inc. Targets for therapeutic intervention identified in the mitochondrial proteome
US20040001859A1 (en) 2002-06-28 2004-01-01 Cheung Ling Yuk Anti-aging dietary supplements
JP2006240990A (ja) 2003-05-15 2006-09-14 Kirin Brewery Co Ltd ｋｌｏｔｈｏタンパク質および抗ｋｌｏｔｈｏタンパク質抗体ならびにそれらの用途
EP2152295B1 (en) 2007-05-08 2018-04-18 Tel HaShomer Medical Research Infrastructure and Services Ltd. Klotho protein and related compounds for the treatment of cancer
US8420088B2 (en) * 2008-01-28 2013-04-16 Novartis Ag Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en) 2008-01-28 2009-09-01 Novartis Ag Methods and compositions using Klotho-FGF fusion polypeptides
CN101711779B (zh) * 2008-10-08 2012-12-05 中南大学 垫状卷柏提取物在制备抗阿尔茨海默病药物中的用途
CA2783555A1 (en) 2009-12-16 2011-07-14 Eli Lilly And Company Therapeutic uses of soluble alpha-klotho
US20110195077A1 (en) * 2010-01-29 2011-08-11 Novartis Ag Methods and compositions using fgf23 fusion ppolypeptides
JP2012184184A (ja) * 2011-03-04 2012-09-27 Nara Medical Univ 抗老化作用を有するヤドリギ抽出物
AU2015356643B2 (en) 2014-12-04 2019-01-24 Novartis Ag Methods and compositions using Klotho variant polypeptides
CN107405382A (zh) 2015-02-06 2017-11-28 加利福尼亚大学董事会 用于改善认知的方法和组合物
WO2017085317A1 (en) 2015-11-19 2017-05-26 Universitat Autonoma De Barcelona Secreted splicing variant of mammal klotho as a medicament for cognition and behaviour impairments

Also Published As

Publication number Publication date
HK1246193A1 (zh) 2018-09-07
AU2016215080A1 (en) 2017-08-17
CN107405382A (zh) 2017-11-28
AU2016215080B2 (en) 2020-12-24
JP2018509393A (ja) 2018-04-05
WO2016127097A1 (en) 2016-08-11
AU2020281046A1 (en) 2021-01-07
EP3253403A4 (en) 2018-09-26
CN121102455A (zh) 2025-12-12
US10864256B2 (en) 2020-12-15
US20210069305A1 (en) 2021-03-11
US20240108698A1 (en) 2024-04-04
EP3253403A1 (en) 2017-12-13
US20250161418A1 (en) 2025-05-22
US10632180B2 (en) 2020-04-28
US20200230214A1 (en) 2020-07-23
CA2974988A1 (en) 2016-08-11
EP3253403B1 (en) 2021-09-01
US11738070B2 (en) 2023-08-29
US12239694B2 (en) 2025-03-04
AU2020281046B2 (en) 2024-04-18
EP3957317A1 (en) 2022-02-23
US10300117B2 (en) 2019-05-28
US20180015151A1 (en) 2018-01-18
US20180256688A1 (en) 2018-09-13

Similar Documents

Publication Publication Date Title
JP6794363B2 (ja) 認知の向上のための方法および組成物
Plemel et al. Remyelination therapies: a new direction and challenge in multiple sclerosis
Lu et al. Blood tau‐PT217 contributes to the anesthesia/surgery‐induced delirium‐like behavior in aged mice
JP2011513493A (ja) 血液脳関門透過性の調節方法
KR20190135059A (ko) 혈장 및 혈장 산물로 인지 및 운동 장애를 치료하기 위한 투여 요법
EA029023B1 (ru) Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера
Kobayashi et al. Antisense knockdown of drebrin A, a dendritic spine protein, causes stronger preference, impaired pre-pulse inhibition, and an increased sensitivity to psychostimulant
Scott et al. New and emerging drug and gene therapies for Friedreich ataxia
Wang et al. Ginsenoside Rg1 alleviates chronic stress-induced depression in rats by targeting Cx43-YAP axis
US20230181691A1 (en) Platelet factors and cognitive improvement
Zhang et al. A humanized Gs-coupled DREADD for circuit and behavior modulation
EP3920887B1 (en) A phosphatidylinositol-glycan-specific phospholipase d1 (gpld1) polypeptide for use in a method of treating or preventing age-related cognitive dysfunction
Malekzadeh Shafaroudi et al. The relationship between glutamate and multiple sclerosis
Zhang et al. Cholecystokinin B receptor agonists alleviates anterograde amnesia in CCK-deficient and aged Alzheimer's disease mice
HK40070785A (en) Methods and compositions for improved cognition
US20230181687A1 (en) Methods and Compositions for Treatment of Age-Related Dysfunction
TW202434279A (zh) 用於改善認知之方法
Choudhury et al. Movement disorders and translational research
Angelini Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of duchenne muscular dystrophy
Bianco et al. We report 2 cases of adult-onset ECD with neu-rologic involvement and strikingly similar brain MRI pattern of abnormalities.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190204

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200601

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201109

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201111

R150 Certificate of patent or registration of utility model

Ref document number: 6794363

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250